Abraxis BioScience, Inc. today announced that its randomized registrational Phase 3 clinical trial comparing ABRAXANE® (protein-bound paclitaxel) with Taxol® (paclitaxel) injection, both in unity with carboplatin, met the study’s primary endpoint by demonstrating that ABRAXANE showed a meaning upgrade




if (lexico_globals.googleafc.ads.content.length)
{
document.write(lexico_globals.googleafc.ads.contenttop);
document.write(lexico_globals.googleafc.ads.sponsoredlinks);
document.write(lexico_globals.googleafc.ads.content[2]);
document.write("" in overall third edition by the editors of the stars and stripes heritage dictionary. copyright 2003 rate as compared to Taxol, in the first-line regimen of career with farthest non-small cell lung cancer (NSCLC), as assessed by autonomy radiologist review.

More: - Brought to my attention by